CuraTeQ Biologics achieves milestone in Omalizumab biosimilar development
CuraTeQ Biologics Private Limited, a fully integrated arm of Aurobindo Pharma Ltd, has announced significant progress in its biosimilar program, revealing that its Omalizumab biosimilar ... Read More
Novartis’ remibrutinib shows promising results in Phase III studies for chronic spontaneous urticaria
Novartis has revealed encouraging data from the Phase III REMIX-1 and REMIX-2 studies. The studies focused on remibrutinib, a highly selective, oral Bruton’s tyrosine kinase ... Read More